Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | HTR7 | P34969 | 6/20 | 0.57 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2149426 | 0.94 | P2RX7 (0.64) | CYP2D6CYP2C9HPGDCHRM1HTR7 | |
| SCHEMBL2149702 | 0.94 | CHRM1 (0.62) | CYP2D6CYP2C9HPGDCHRM1HTR7 | |
| SCHEMBL2149147 | 0.91 | P2RX7 (0.62) | CYP2D6CYP2C9HPGDCHRM1HTR7 | |
| SCHEMBL2150070 | 0.81 | P2RX7 (0.59) | CYP2D6CYP2C9HPGDCHRM1HTR7 | |
| SCHEMBL2149940 | 0.81 | P2RX7 (0.68) | CYP2D6CYP2C9HPGDCHRM1HTR7 | |
| SCHEMBL2150225 | 0.79 | LMNA (0.67) | CYP2D6CYP2C9CHRM1HTR7P2RX7 | |
| SCHEMBL30216825 | 0.79 | HTR7 (0.73) | CYP2D6CYP2C9CHRM1HTR7P2RX7 | |
| SCHEMBL4042957 | 0.78 | LMNA (0.79) | CYP2D6CYP2C9HPGDCHRM1HTR7 | |
| SCHEMBL3036994 | 0.78 | LMNA (0.70) | CYP2D6CYP2C9CHRM1HTR7P2RX7 | |
| SCHEMBL6902600 | 0.78 | RAB9A (0.72) | CYP2D6CYP2C9HPGDCHRM1HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432420-B1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARM INC (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20100216840-A1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20090209525-A1 | ENABLING METHODS TO IDENTIFY ALLOSTERIC MODULATORS OF RECEPTOR ACTIVITY | SPALDING TRACY A | 2009-08-20 | — | — | US | disclosed |
| US-20090209525-A1 | ENABLING METHODS TO IDENTIFY ALLOSTERIC MODULATORS OF RECEPTOR ACTIVITY | SPALDING TRACY A | 2009-08-20 | — | — | US | disclosed |
| US-20080070948-A1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080009520-A1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2008-01-10 | — | — | US | disclosed |
| WO-2008005063-A2 | ENABLING METHODS TO IDENTIFY ALLOSTERIC MODULATORS OF RECEPTOR ACTIVITY | ACADIA PHARMACEUTICALS INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| US-7300928-B2 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-7291611-B2 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7273857-B2 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-20060258707-A1 | Benzimidazolidinone derivatives as muscarinic agents | KELLY NICHOLAS M | 2006-11-16 | — | — | US | disclosed |
| US-20060205785-A1 | Benzimidazolidinone derivatives as muscarinic agents | KELLY NICHOLAS M | 2006-09-14 | — | — | US | disclosed |
| US-20060199799-A1 | Benzimidazolidinone derivatives as muscarinic agents | KELLY NICHOLAS M | 2006-09-07 | — | — | US | disclosed |
| US-7087593-B2 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS INC. (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060025402-A1 | Benzimidazolidinone derivatives as muscarinic agents | KELLY NICHOLAS M | 2006-02-02 | — | — | US | disclosed |
| US-6951849-B2 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS INC. (US) | 2005-10-04 | — | — | US | disclosed |
| US-20040067931-A1 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS INC. | 2004-04-08 | — | — | US | disclosed |
| US-20030100545-A1 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS, INC. | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070948-A1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | CHRM4, CHRM1, CHRM2 | CYP2D6 2195/4885CYP2C9 2511/4885HPGD 2819/4885 |
| US-20090209525-A1 | ENABLING METHODS TO IDENTIFY ALLOSTERIC MODULATORS OF RECEPTOR ACTIVITY | GRK2, GRM2, GRK4 | CYP2D6 2681/4885CYP2C9 3922/4885HPGD 3094/4885 |
| US-20030100545-A1 | Benzimidazolidinone derivatives as muscarinic agents | CHRM4, CHRM5, CHRM1 | CYP2D6 2683/4885CYP2C9 2993/4885HPGD 2776/4885 |
| US-20060258707-A1 | Benzimidazolidinone derivatives as muscarinic agents | CHRM4, CHRM1, CHRM2 | CYP2D6 2195/4885CYP2C9 2511/4885HPGD 2819/4885 |
| US-20100216840-A1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | CHRM4, CHRM1, CHRM2 | CYP2D6 2195/4885CYP2C9 2511/4885HPGD 2819/4885 |
| US-20060025402-A1 | Benzimidazolidinone derivatives as muscarinic agents | CHRM4, CHRM1, CHRM2 | CYP2D6 2195/4885CYP2C9 2511/4885HPGD 2819/4885 |
| US-20080009520-A1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | CHRM4, CHRM1, CHRM2 | CYP2D6 2195/4885CYP2C9 2511/4885HPGD 2819/4885 |
| US-20040067931-A1 | Benzimidazolidinone derivatives as muscarinic agents | CHRM4, CHRM5, CHRM1 | CYP2D6 2683/4885CYP2C9 2993/4885HPGD 2776/4885 |
| US-20060199799-A1 | Benzimidazolidinone derivatives as muscarinic agents | CHRM4, CHRM1, CHRM2 | CYP2D6 2195/4885CYP2C9 2511/4885HPGD 2819/4885 |
| US-20060205785-A1 | Benzimidazolidinone derivatives as muscarinic agents | CHRM4, CHRM1, CHRM2 | CYP2D6 2195/4885CYP2C9 2511/4885HPGD 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.